If you would like to learn more about future focusIR related events and roundtables, please submit your details here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSYR.L Share News (SYR)

  • There is currently no data for SYR

Friday broker round-up UPDATE

Fri, 17th Jan 2014 10:05
Aberdeen Asset Management: JP Morgan cuts target price from 544p to 529p, while its overweight rating remains unchanged. Canaccord Genuity reduces target price from 586p to 540p and reiterates a buy recommendation. UBS lowers target price from 540p to 520p and keeps a buy recommendation.Ashtead Group: JP Morgan increases target price from 817p to 913p and stays with its overweight rating.Associated British Foods: Societe Generale raises target price from 2260p to 2600p and reiterates a hold recommendation.AstraZeneca: UBS increases target price from 400p to 4150p and keeps its buy recommendation.Aviva: Goldman Sachs takes target price from 230p to 260p and reiterates a neutral rating.Bovis Homes Group: HSBC increases target price from 1065p to 1125p keeping an overweight rating.Brain Juicer: Canaccord Genuity takes target price from 298p to 350p retaining its buy recommendation.Croda International: UBS moves target price from 2500p to 2525p maintaining its neutral rating.CSR: Liberum Capital raises target price from 580p to 700p, while downgrading to hold.Diageo: JP Morgan reduces target price from 2050p to 1970p downgrading to neutral.Dixons Retail: Investec lowers target price from 62p to 56p keeping its buy recommendation. UBS shapes target price from 60p to 58p leaving its buy recommendation unchanged.Domino Printing: UBS increases target price from 720p to 840p reiterating a neutral rating.Experian: Canaccord Genuity reduces target price from 905p to 858p retaining its sell recommendation.F&C Asset Management: Canaccord Genuity cuts target price from 130p to 110p and downgrades from buy to hold.First Group: Panmure Gordon ups target price from 120p to 140p and reiterates its hold recommendation.Halfords Group: Citi shifts target price from 545p to 550p and stays with its buy recommendation.Harvey Nash: Panmure Gordon moves target price from 126p to 135p retaining a buy recommendation.Hays: Liberum Capital starts with a target price of 170p and a buy recommendation.Home Retail: Deutsche Bank shifts target price from 225p to 230p maintaining a buy recommendation. Societe Generale ups target price from 158p to 175p, while still recommending selling. Citi moves target price from 195p to 205p and retains a neutral rating. HSBC ups target price from 220p to 250p and reiterates its overweight rating. Nomura moves target price from 215p to 230p and maintains a buy recommendation.Inchcape: Panmure Gordon raises target price from 675p to 750p and reiterates a buy recommendation.Informa: Westhouse Securities shifts target price from 570p to 580p and leaves its neutral rating unaltered.Intertek Group: Credit Suisse reduces target price from 3500p to 3200p downgrading to neutral.Jupiter Fund Management: Espirito Santo raises target price from 429p to 465p and leaves its buy recommendation unchanged.Legal & General Group: Goldman Sachs moves target price from 205p to 215p and maintains a neutral rating.Morrison (Wm: Societe Generale starts with a target price of 200p and a sell recommendation.Michael Page: Liberum Capital initiates with a target price of 575p and a buy recommendation.Optos: Panmure Gordon takes target price from 206p to 235p keeping a buy recommendation.Petrofac: Nomura raises target price from 1300p to 1430p upgrading to buy.Premier Oil: Deutsche Bank cuts target price from 520p to 500p and retains a buy recommendation. Societe Generale reduces target price from 385p to 320p downgrading to hold. Liberum Capital ups target price from 300p to 320p and keeps a hold recommendation. UBS cuts target price from 400p to 350p retaining a buy recommendation.Prudential: Goldman Sachs ups target price from 1500p to 1580p and keeps a strong buy recommendation.Renew Holdings: WH Ireland takes target price from 190p to 235p and reiterates its buy recommendation.Resolution: Goldman Sachs shifts target price from 335p to 340p and maintains a neutral rating.Rio Tinto: JP Morgan raises target price from 4400p to 4500p leaving its overweight rating unchanged. UBS moves target price from 4040p to 4050p and keeps a buy recommendation.Robert Walters: Liberum Capital starts with a target price of 415p and a buy recommendation.Royal Bank of Scotland: Investec moves target price from 335p to 345p, while downgrading to sell.Sainsbury: Societe Generale initiates with a target price of 370p and a hold recommendation.Smith (DS): Berenberg starts with a target price of 400p and a buy recommendation.Standard Life: Goldman Sachs ups target price from 320p to 335, but still keeps a sell recommendation.SThree: Liberum Capital initiates with a target price of 475p and a buy recommendation.St James's Place: Goldman Sachs increases target price from 770p to 810p and retains a buy recommendation. JP Morgan raises target price from 724p to 811p leaving its overweight rating unaltered.Surgical Innovations: Panmure Gordon downgrades from buy to hold with a target price of 5p.Synergy Health: Investec reduces target price from 1650p to 1400p leaving its buy recommendation unaltered.Synthomer: UBS ups target price from 255p to 280p, while downgrading from buy to neutral.Tesco: Societe Generale cuts target price from 290p to 270p keeping its sell recommendation.Tribal Group: Canaccord Genuity ups target price from 221p to 240p and stays with its buy recommendation. WH Ireland takes target price from 235p to 260p retaining a buy recommendation.Tullow Oil: Liberum Capital reduces target price from 1445p to 1367p, while its buy recommendation remains unchanged.Unilever: Panmure Gordon reduces target price from 2525p to 2280p retaining its hold recommendation.

Related News

Hutchmed drug approved in China for advanced gastric cancer
2 hours ago

Hutchmed drug approved in China for advanced gastric cancer

(Alliance News) - Hutchmed China Ltd on Thursday announced regulatory approval for savolitinib, brand name 'ORPATHYS', for a form of gastric cancer wi...

AstraZeneca signs CSPC China deal for experimental kidney disease drugs
6 hours ago

AstraZeneca signs CSPC China deal for experimental kidney disease drugs

July 2 (Reuters) - AstraZeneca โ€‹has entered into a deal worth up to $1.77 billion โ€‹with โ€ŒCSPC Pharmaceutical Group to discover and develop experimenta...

WINNERS & LOSERS: Capricorn jumps after agreeing to Genel takeover
6 hours ago

WINNERS & LOSERS: Capricorn jumps after agreeing to Genel takeover

(Alliance News) - The following are the leading risers and fallers among London Main Market small-cap and AIM stocks on Thursday.

SYR.L News

Synergy Health makes offer for outstanding SRI stock
14 Jun 2012

Synergy Health makes offer for outstanding SRI stock

Synergy Health, a provider of outsourced sterilisation services, has commenced a tender offer through its wholly-owned subsidiary, SHM Acquisition, fo...

Tuesday broker round-up
12 Jun 2012

Tuesday broker round-up

Amlin: Deutsche Bank upgrades to buy, target lifted from 420p to 435p. British Sky Broadcasting: Morgan Stanley upgrades to overweight, 790p target m...

Broker tips: Centamin, Synergy Health, Halfords
7 Jun 2012

Broker tips: Centamin, Synergy Health, Halfords

Nomura has upgraded its rating for Egyptian gold miner Centamin from neutral to buy and increased its target price from 100p to 130p, saying that oper...

Broker snap: Investec stays optimistic about Synergy Health
7 Jun 2012

Broker snap: Investec stays optimistic about Synergy Health

Investec has reiterated its buy recommendation and 980p target price for healthcare services outsourcer Synergy Health, saying that the shares look ov...

Thursday broker round-up
7 Jun 2012

Thursday broker round-up

Barclays: Deutsche Bank retains buy rating and 295p target. Burberry: Credit Suisse upgrades to outperform, target lifted from 1,420p to 1,650p. Cen...

Synergy taps market as buying spree continues
7 Jun 2012

Synergy taps market as buying spree continues

After going on an acquisition spree over the last 14 months Synergy Health, the provider of outsourced sterilisation services, is to bolster its balan...

Synergy Health on track to meet earnings forecasts
12 Apr 2012

Synergy Health on track to meet earnings forecasts

Synergy Health, the provider of outsourced sterilisation services,has said that trading in the last quarter of its fiscal year has been in line with e...

Synergy Health appoints Asian specialist to the board
3 Apr 2012

Synergy Health appoints Asian specialist to the board

Synergy Health, the provider of outsourced sterilisation services, has appointed Niclas Ollson to the senior executive board as Chief Executive Office...